A brief review on high on-aspirin residual platelet reactivity

Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been name...

Full description

Saved in:
Bibliographic Details
Published inVascular pharmacology Vol. 67-69; pp. 6 - 9
Main Authors Pettersen, A.A., Arnesen, H., Seljeflot, I.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2015
Subjects
Online AccessGet full text
ISSN1537-1891
1879-3649
DOI10.1016/j.vph.2015.03.018

Cover

Loading…
More Information
Summary:Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been named aspirin resistance, aspirin non-responsiveness or high-on-aspirin residual platelet reactivity. The mechanism of aspirin antiplatelet effect is due to the inhibition of cyclooxygenase-1 enzyme in platelets. In some trials, almost all patients on aspirin have a very low level of serum thromboxane B2, indicating that the measured platelet reactivity in aspirin-treated patients might be due to platelet activation via other pathways, such as ADP or thrombin. The prevalence of real aspirin resistance seems to be very low, and probably the term “high-on-aspirin residual platelet reactivity” should be preferred to describe this phenomenon. [Display omitted]
ISSN:1537-1891
1879-3649
DOI:10.1016/j.vph.2015.03.018